Fifth US Biosimilar To Herceptin Launched By Merck
Ontruzant Biosimilar Available For All Eligible Indications
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.
You may also be interested in...
Organon has launched its Ontruzant trastuzumab biosimilar version of Herceptin and its Aybintio bevacizumab rival to Avastin in Canada. The launches come shortly after the firm revealed biosimilars sales that were slightly down in Q3.
Samsung Bioepis has received approval from Health Canada for its Ontruzant trastuzumab biosimilar rival to Herceptin in 150mg single-use and 440mg multi-dose vials. The product will be marketed in Canada by Organon.
Sandoz has filed the proposed trastuzumab biosimilar developed by partner EirGenix with the US FDA. If approved, the product will have to compete in an already busy market for Herceptin biosimilars.